Rezolute’s Promising Outlook: Buy Rating Backed by Strong Clinical Progress and Financial Position

Analyst Jason McCarthy from Maxim Group maintained a Buy rating on Rezolute (RZLT – Research Report) and keeping the price target at $15.00.

Jason McCarthy has given his Buy rating due to a combination of factors that highlight Rezolute’s promising outlook. The company’s Phase 3 sunRIZE study for the monoclonal antibody ersodetug in treating congenital hyperinsulinism (CHI) has exceeded its enrollment target, which is a positive indicator of the study’s potential success. The top-line data from this study, expected in December 2025, serves as a significant catalyst for Rezolute’s stock, suggesting a favorable future for the company’s market performance.
Additionally, Rezolute’s financial position is strong, with substantial cash reserves that support ongoing and future clinical developments. The upcoming Phase 3 study for tumor hyperinsulinism, anticipated to start mid-2025, further adds to the company’s growth prospects. The potential for commercialization of ersodetug in both CHI and tumor hyperinsulinism by 2027 and 2028, respectively, underpins the Buy rating, as these developments could lead to significant revenue generation for Rezolute.

In another report released today, Craig-Hallum also reiterated a Buy rating on the stock with a $13.00 price target.

RZLT’s price has also changed moderately for the past six months – from $4.990 to $3.950, which is a -20.84% drop .